Pralsetinib in Patients with RET Fusion–Positive Non-Small-Cell Lung Cancer: A Plain Language Summary of the ARROW Study

Frank Griesinger1 Pius-Hospital, University of Oldenburg, Oldenburg, Germany

Giuseppe Curigliano2 European Institute of Oncology, IRCCS, Milan, Italy;3 University of Milano, Milan, Italy

Vivek Subbiah4 Sarah Cannon Research Institute, Nashville, TN, USA

Christina S Baik5 University of Washington School of Medicine, Seattle, WA, USA

Daniel SW Tan6 National Cancer Centre Singapore, Singapore

Dae H Lee7 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Daniel Misch8 Helios Clinic Emil von Behring, Berlin, Germany

Elena Garralda9 Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Dong-Wan Kim10 Seoul National University College of Medicine & Seoul National University Hospital, Seoul, Republic of Korea

Anthonie J van der Wekken11 University of Groningen & University Medical Center Groningen, Groningen, Netherlands

Justin F Gainor12 Massachusetts General Hospital, Boston, MA, USA

Luis Paz-Ares13 Hospital Universitario 12 de Octubre, Madrid, Spain

Stephen V Liu14 Georgetown University, Washington, DC, USA

Gregory P Kalemkerian15 University of Michigan, Ann Arbor, MI, USA

Daniel W Bowles16 University of Colorado School of Medicine, Aurora, CO, USA

Aaron S Mansfield17 Mayo Clinic, Rochester, NY, USA

Jessica J Lin12 Massachusetts General Hospital, Boston, MA, USA

Vlatka Smoljanovic18 F. Hoffmann-La Roche, Ltd, Basel, Switzerland

Ahmadur Rahman18 F. Hoffmann-La Roche, Ltd, Basel, Switzerland

Alena Zalutskaya19 Blueprint Medicines Corporation, Cambridge, MA, USA

Melinda Louie-Gao19 Blueprint Medicines Corporation, Cambridge, MA, USA

Andy L Boral19 Blueprint Medicines Corporation, Cambridge, MA, USA

Julien Mazières20 Institut Universitaire du Cancer, Toulouse, France

Your download is now in progress and you may close this window